Miracle Mile Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Miracle Mile Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,938	Closed	-$232K	–	640
2024 Q3	$232K	Sell	4,938 -110	-2%	-$5.58K	0.01%	474
2024 Q2	$273K	Hold	5,048	–	–	0.01%	423
2024 Q1	$344K	Hold	5,048	–	–	0.01%	387
2023 Q4	$316K	Hold	5,048	–	–	0.01%	387
2023 Q3	$229K	Hold	5,048	–	–	0.01%	437
2023 Q2	$283K	Hold	5,048	–	–	0.01%	428
2023 Q1	$228K	Hold	5,048	–	–	0.01%	461
2022 Q4	$205K	Hold	5,048	–	–	0.01%	470
2022 Q3	$330K	Buy	+5,048	New	+$366K	0.02%	348
2021 Q4	–	Sell	-3,501	Closed	-$392K	–	451
2021 Q3	$392K	Buy	3,501 +110	+3%	+$13.8K	0.02%	325
2021 Q2	$549K	Buy	+3,391	New	+$412K	0.03%	249

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Miracle Mile Advisors's CRSP Position: Q4 2024 in Review

Miracle Mile Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2024, closing a stake of 4,938 shares — an estimated $232K sold.

Miracle Mile Advisors first reported a position in CRSP in Q2 2021 and held it in 11 quarters. The position peaked at $549K in Q2 2021. 404 funds tracked by Wall St. Rank hold CRSP as of Q4 2024.

Miracle Mile Advisors reported no remaining CRISPR Therapeutics position as of Q4 2024 after selling out during the quarter.
Miracle Mile Advisors sold 4,938 CRISPR Therapeutics shares in Q4 2024, an estimated $232K.
Miracle Mile Advisors first reported a position in CRISPR Therapeutics in Q2 2021 and held it in 11 quarters.
Miracle Mile Advisors's CRISPR Therapeutics position peaked at $549K in Q2 2021.
404 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2024.

Based on Miracle Mile Advisors's 13F filing for Q4 2024, filed 13 Jan 2025.